» Articles » PMID: 27512866

Venous Thromboembolism Has the Same Risk Factors As Atherosclerosis: A PRISMA-compliant Systemic Review and Meta-analysis

Overview
Specialty General Medicine
Date 2016 Aug 12
PMID 27512866
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Previous studies have shown that idiopathic pulmonary embolism is positively associated with other cardiovascular events, such as myocardial infarction and stroke, suggesting a potentially important association between atherosclerosis risk factors and venous thromboembolism (VTE). We performed a meta-analysis to evaluate the correlation between risk factors for atherosclerosis and VTE.

Methods: In December 2014, we searched MEDLINE and EMBASE for studies evaluating the associations between VTE and risk factors for atherosclerosis and pooled outcome data using random-effects meta-analysis. In addition, we analyzed publication bias.

Results: Thirty-three case-control and cohort studies with a total of 185,124 patients met the inclusion criteria. We found that participants with body mass index (BMI) ≥30 kg/m had a significantly higher prevalence of VTE than those with BMI <30 kg/m in both case-control studies (odds ratio [OR] = 2.45, 95% confidence interval [CI]: 1.78-3.35) and cohort studies (relative risk [RR] = 2.39, 95% CI: 1.79-3.17). VTE was more prevalent in patients with hypertension than without hypertension (OR = 1.40, 95% CI: 1.06-1.84; RR = 1.36, 95% CI: 1.11-1.67). The findings were similar for VTE prevalence between patients with and without diabetes (OR = 1.78, 95% CI: 1.17-2.69; RR = 1.41, 95% CI: 1.20-1.66). Current smoking was significantly associated with VTE prevalence in case-control studies (OR = 1.34, 95% CI: 1.01-1.77), but not in cohort studies (RR = 1.29, 95% CI: 0.96-1.72). In addition, we found that total cholesterol and triglyceride concentrations were significantly higher in patients with VTE than without VTE (weighted mean differences [WMD] = 8.94 mg/dL, 95% CI: 3.52-14.35 mg/dL, and WMD = 14.00 mg/dL, 95% CI: 8.85-19.16 mg/dL, respectively). High-density lipoprotein cholesterol concentrations were significantly lower in patients with VTE than without VTE (WMD = -2.03 mg/dL, 95% CI: -3.42 to -0.63 mg/dL). Higher quality studies were more homogeneous, but confirmed the same significant associations.

Conclusions: Based on our systematic review and meta-analysis, we observed a significant association between VTE and the risk factors for atherosclerosis. These results may make an important contribution to clinical practice regarding VTE treatment.

Citing Articles

Genetic correlation between genes targeted by lipid-lowering drugs and venous thromboembolism: A drug-target Mendelian randomization study.

Li M, Duan H, Luo J, Tan Y, Liu M, Zhao X Medicine (Baltimore). 2024; 103(51):e40770.

PMID: 39705479 PMC: 11666180. DOI: 10.1097/MD.0000000000040770.


Apelin-13 as a novel diagnostic laboratory biomarker in thromboembolic disorders: a review of literature with prospective insights.

Karimi M, Shirsalimi N, Sedighi E Int J Emerg Med. 2024; 17(1):190.

PMID: 39695958 PMC: 11658133. DOI: 10.1186/s12245-024-00774-3.


Allometric fat mass index and alanine aminotransferase attenuate the associations of platelet parameters with lung cancer risk.

Christakoudi S, Tsilidis K, Gunter M, Riboli E Sci Rep. 2024; 14(1):26318.

PMID: 39487349 PMC: 11530616. DOI: 10.1038/s41598-024-78281-x.


Role of PCSK9 inhibitors in venous thromboembolism: current evidence and unmet clinical needs.

Zuin M, Corsini A, Dalla Valle C, De Rosa C, Maloberti A, Mojoli M Eur Heart J Cardiovasc Pharmacother. 2024; 10(8):719-724.

PMID: 39406397 PMC: 11724145. DOI: 10.1093/ehjcvp/pvae076.


Causes of death after first time venous thromboembolism.

Lonnberg F, Roos A, Farm M, Heurlin A, Okas M, Gigante B Thromb J. 2024; 22(1):16.

PMID: 38303070 PMC: 10832181. DOI: 10.1186/s12959-024-00586-8.


References
1.
Doggen C, Smith N, Lemaitre R, Heckbert S, Rosendaal F, Psaty B . Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2004; 24(10):1970-5. DOI: 10.1161/01.ATV.0000143134.87051.46. View

2.
Finucane M, Stevens G, Cowan M, Danaei G, Lin J, Paciorek C . National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011; 377(9765):557-67. PMC: 4472365. DOI: 10.1016/S0140-6736(10)62037-5. View

3.
Pomp E, le Cessie S, Rosendaal F, Doggen C . Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol. 2007; 139(2):289-96. DOI: 10.1111/j.1365-2141.2007.06780.x. View

4.
Tsai A, Cushman M, Rosamond W, Heckbert S, Polak J, Folsom A . Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002; 162(10):1182-9. DOI: 10.1001/archinte.162.10.1182. View

5.
Ceriello A, Giugliano D, Quatraro A, dello Russo P, Torella R . Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia. 1988; 31(12):889-91. DOI: 10.1007/BF00265372. View